Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. Now, a monoclonal antibody, named BION-1301 (anti-APRIL), is being developed to treat patients with IgA nephropathy.
BION-1301 is a potential disease-modifying approach to prevent the formation of immune complexes that deposit in the glomeruli of the kidney, causing damage. BION-1301 was developed in a TIP Pharma consortium by prof. Jan Paul Medema and dr. Hans van Eenennaam partly at the Amsterdam UMC and is now a pipeline product of Chinook Therapeutics, which recently reported that during the phase 1 trial, healthy volunteers well-tolerated BION-1301 with no serious adverse events, a pharmacokinetic half-life of approximately 33 days. The antibody demonstrated dose-dependent pharmacodynamic effects characterized by durable reductions in serum levels of free APRIL, IgA, galactose-deficient IgA (Gd-IgA1) and IgM, with a lesser reduction in IgG. Now, BION-1301 is evaluated in patients with IgA nephropathy in a phase 1b trial.
Chinook Therapeutics
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
World Congress of Nephrology 2021
The ongoing phase 1 multi-center trial was presented at World Congress of Nephrology 2021.
For more information see WCN21-0706: A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes.
Sem Vijverberg – PhD Candidate at Vrije Universiteit Amsterdam – and University of Amsterdam PostDoc researcher Tijmen Bakker have been selected as participants in the Faculty of Impact, and will be taking part in an intensive two year program where ten ambitious scientists work with each other and with a selection of experts to conquer […]
NewsAnya Biotech, representing Amsterdam UMC, has won the second edition of the Proefdiervrij Venture Challenge on the 22nd of April 2022. Their winning innovation is based on research from the Department of Medical Biology at the AMC. The team takes home €25.000, – in prize money to kick-start their venture based on human heart models […]
NewsEvery language contains riddles and secrets, currently there are seven thousand+ known languages. A treasure trove of colourful, curious and enigmatic stories. Every language tells a story about and gives a picture of the culture and the people that speak or have spoken this language. And every language is full of riddles and secrets that […]
News